Levodopa in Parkinsonism.
D001921:Brain / Q000378:metabolism; D001923:Brain Chemistry; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004298:Dopamine / Q000032:analysis / Q000096:biosynthesis; D004357:Drug Synergism; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009638:Norepinephrine / Q000032:analysis; D010300:Parkinson Disease / Q000188:drug therapy*; D011379:Prognosis; D012701:Serotonin / Q000032:analysis; D013997:Time Factors
D012701:Serotonin; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine